Healthcare provider profile · identity verified

Mark R Beahm, M.D.

Family Practice · ONALASKA, WI · NPI 1689908360

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	543	162
Amlodipine Besylate	Amlodipine Besylate	274	83
Losartan Potassium	Losartan Potassium	263	79
Lisinopril	Lisinopril	245	76
Omeprazole	Omeprazole	236	79
Hydrochlorothiazide	Hydrochlorothiazide	198	61
Metoprolol Succinate	Metoprolol Succinate	190	55
Levothyroxine Sodium	Levothyroxine Sodium	188	58
Eliquis	Apixaban	164	34
Simvastatin	Simvastatin	148	45
Tamsulosin Hcl	Tamsulosin Hcl	146	43
Warfarin Sodium	Warfarin Sodium	129	32
Metformin Hcl Er	Metformin Hcl	112	30
Pantoprazole Sodium	Pantoprazole Sodium	112	31
Sertraline Hcl	Sertraline Hcl	111	35
Metoprolol Tartrate	Metoprolol Tartrate	109	28
Tramadol Hcl	Tramadol Hcl	96	29
Gabapentin	Gabapentin	91	29
Rosuvastatin Calcium	Rosuvastatin Calcium	91	26
Ozempic	Semaglutide	86	16
Jardiance	Empagliflozin	84	24
Furosemide	Furosemide	82	20
Metformin Hcl	Metformin Hcl	80	27
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	79	13
Trazodone Hcl	Trazodone Hcl	78	22
Albuterol Sulfate Hfa	Albuterol Sulfate	72	34
Butorphanol Tartrate	Butorphanol Tartrate	72	suppressed
Allopurinol	Allopurinol	70	23
Duloxetine Hcl	Duloxetine Hcl	69	19
Alendronate Sodium	Alendronate Sodium	67	18
Azelastine Hcl	Azelastine Hcl	58	21
Fluoxetine Hcl	Fluoxetine Hcl	58	19
Pravastatin Sodium	Pravastatin Sodium	58	19
Trulicity	Dulaglutide	58	13
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	57	23
Tizanidine Hcl	Tizanidine Hcl	57	suppressed
Mirtazapine	Mirtazapine	56	14
Potassium Chloride	Potassium Chloride	56	17
Oxycodone Hcl	Oxycodone Hcl	54	13
Spironolactone	Spironolactone	53	18
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	51	14
Lorazepam	Lorazepam	49	13
Bupropion Xl	Bupropion Hcl	46	14
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	45	15
Finasteride	Finasteride	45	16
Fluticasone Propionate	Fluticasone Propionate	45	23
Mounjaro	Tirzepatide	45	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	41	12
Zolpidem Tartrate	Zolpidem Tartrate	41	suppressed
Clonazepam	Clonazepam	40	suppressed
Meloxicam	Meloxicam	39	16
Clopidogrel	Clopidogrel Bisulfate	37	11
Famotidine	Famotidine	37	13
Paroxetine Hcl	Paroxetine Hcl	37	suppressed
Xarelto	Rivaroxaban	37	suppressed
Atenolol	Atenolol	35	suppressed
Bisoprolol Fumarate	Bisoprolol Fumarate	34	suppressed
Entresto	Sacubitril/Valsartan	34	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	33	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	33	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	31	12
Nitroglycerin	Nitroglycerin	30	17
Glimepiride	Glimepiride	29	suppressed
Lamotrigine	Lamotrigine	29	suppressed
Montelukast Sodium	Montelukast Sodium	28	11
Ondansetron Odt	Ondansetron	28	suppressed
Topiramate	Topiramate	28	suppressed
Chlorthalidone	Chlorthalidone	27	suppressed
Pregabalin	Pregabalin	27	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	27	18
Venlafaxine Hcl Er	Venlafaxine Hcl	27	11
Diazepam	Diazepam	26	suppressed
Glipizide Er	Glipizide	25	suppressed
Lovastatin	Lovastatin	25	suppressed
Prednisone	Prednisone	25	14
Temazepam	Temazepam	25	suppressed
Torsemide	Torsemide	25	suppressed
Cefadroxil	Cefadroxil	24	suppressed
Ezetimibe	Ezetimibe	23	suppressed
Diclofenac Sodium	Diclofenac Sodium	22	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	22	suppressed
Carvedilol	Carvedilol	21	suppressed
Celecoxib	Celecoxib	21	suppressed
Meclizine Hcl	Meclizine Hcl	21	suppressed
Spiriva Respimat	Tiotropium Bromide	21	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	21	suppressed
Baclofen	Baclofen	20	suppressed
Fenofibrate	Fenofibrate	20	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	18	suppressed
Bumetanide	Bumetanide	17	suppressed
Citalopram Hbr	Citalopram Hydrobromide	17	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	17	suppressed
Creon	Lipase/Protease/Amylase	15	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	15	suppressed
Farxiga	Dapagliflozin Propanediol	15	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	15	suppressed
Levetiracetam	Levetiracetam	15	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	14	suppressed
Donepezil Hcl	Donepezil Hcl	14	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	14	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	14	suppressed
Amoxicillin	Amoxicillin	13	suppressed
Carbidopa-Levodopa	Carbidopa/Levodopa	13	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	13	suppressed
Glipizide	Glipizide	13	suppressed
Hydroxychloroquine Sulfate	Hydroxychloroquine Sulfate	13	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	13	suppressed
Ventolin Hfa	Albuterol Sulfate	13	suppressed
Acyclovir	Acyclovir	12	suppressed
Alprazolam	Alprazolam	12	suppressed
Buspirone Hcl	Buspirone Hcl	12	suppressed
Lantus	Insulin Glargine,hum.Rec.Anlog	12	suppressed
Latanoprost	Latanoprost	12	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	12	suppressed
Toujeo Solostar	Insulin Glargine,hum.Rec.Anlog	12	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	12	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	12	suppressed
Advair Hfa	Fluticasone Propion/Salmeterol	11	suppressed
Invokana	Canagliflozin	11	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	11	suppressed
Ropinirole Hcl	Ropinirole Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error